Clinical trials · California
Locally Advanced or Metastatic Solid Tumors clinical trials in California
We’re tracking 566 recruiting locally advanced or metastatic solid tumors studies with a site in California — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT05805371RecruitingPhase 1
PSCA CAR-T cells with or without radiation for prostate cancer
This Phase 1 study tests a prostate cancer treatment made of PSCA-targeted CAR-T cells, with or without radiation, to help control advanced prostate cancer. It aims to find a safe treatment approach and see how well it works in people whose cancer has PSCA.
Duarte, CaliforniaAges 18 years+ - NCT07191717RecruitingPhase 2
Imlunestrant and abemaciclib for early ER+ breast cancer
This trial tests whether adding two targeted drugs, imlunestrant and abemaciclib, to your usual hormone therapy can lower the chance of your breast cancer coming back. It is for people with early-stage ER+ breast cancer who have no signs of cancer on scans but have tiny amounts of tumor DNA in their blood (called ctDNA).
Los Angeles, CaliforniaAges 18 years+ - NCT06452277RecruitingPhase 3
Testing sevabertinib for advanced HER2-mutated lung cancer
This trial compares a new targeted drug called sevabertinib against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation. The goal is to see if sevabertinib works better and is safe.
Newport Beach, CaliforniaAges 18 years+ - NCT07221357RecruitingPhase 2/Phase 3
Pumitamig plus chemo vs standard care for new colorectal cancer
This trial tests a new drug called Pumitamig combined with chemotherapy against standard bevacizumab plus chemotherapy for people with advanced colorectal cancer that cannot be surgically removed and hasn't been treated yet. The goal is to see which combination works better and is safer.
Los Angeles, CaliforniaAges 18 years+ - NCT05099172RecruitingPhase 1/Phase 2
Study drug for EGFR or HER2-mutated advanced lung cancer
This early-phase study tests a new investigational medicine (BAY2927088) in people with advanced non-small cell lung cancer (NSCLC) that has EGFR and/or HER2 mutations. It’s designed to see how the drug works and what side effects it causes, when standard options have not helped or aren’t suitable.
Duarte, CaliforniaAges 18 years+ - NCT06324357RecruitingPhase 1/Phase 2
Zongertinib for HER2-positive cancers that have spread
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
Cerritos, CaliforniaAges 18 years+ - NCT05797805RecruitingPhase 1/Phase 2
Tegavivint for advanced liver cancer after prior treatments
This early-phase study tests tegavivint in people with advanced hepatocellular carcinoma (HCC), a type of liver cancer. It’s meant for cases where the cancer can’t be treated with curative surgery/local procedures or has progressed after standard systemic medicines.
Duarte, CaliforniaAges 18 years+ - NCT05394831RecruitingPhase 1/Phase 2
Study of an EGFR-targeted drug for advanced lung cancer
This trial tests a new drug (JIN-A02) in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has specific EGFR mutations. It mainly checks whether the treatment is safe and tolerable, and how the body handles the drug, with possible benefit depending on your mutation type.
Orange, CaliforniaAges 18 years+ - NCT04524871RecruitingPhase 1/Phase 2
Immunotherapy combinations for advanced liver cancer
This Phase 1/2 study tests new combinations of immune system medicines in people with advanced liver cancer that cannot be cured by surgery. It looks for safer treatment and signs that the medicines can shrink or control the cancer.
Costa Mesa, CaliforniaAges 18 years+ - NCT06065748RecruitingPhase 3
New hormone therapy for advanced breast cancer after prior treatment
This trial tests a new oral hormone therapy, giredestrant, against a standard hormone therapy (fulvestrant) when both are given with a CDK4/6 inhibitor. It is for people with advanced ER-positive, HER2-negative breast cancer that has come back after initial hormone therapy, and who have not yet had other treatments for advanced disease.
Auburn, CaliforniaAges 18 years+ - NCT06745076RecruitingPhase 2
Using a blood test to safely lower chemo for advanced Hodgkin lymphoma
This trial studies whether a blood test (ctDNA) can help doctors safely reduce chemotherapy for people with advanced Hodgkin lymphoma. If you have stage 3 or 4 Hodgkin lymphoma that hasn't been treated yet and are healthy enough for strong chemo, this study may be an option for you.
Irvine, CaliforniaAges 18 years+ - NCT06264180RecruitingPhase 3
Viral therapy and nivolumab for advanced melanoma
This trial tests a combination of an investigational viral therapy (VO) and the immunotherapy nivolumab for people with advanced melanoma that has stopped responding to previous anti-PD-1 and anti-CTLA-4 treatments. The goal is to see if this combination works better than other standard treatments your doctor might choose.
La Jolla, CaliforniaAges 12 years+ - NCT07043400RecruitingPhase 3
Study comparing two ways to give tislelizumab plus chemo for stomach cancer
This trial compares a shot under the skin versus an IV infusion of tislelizumab, given along with chemotherapy, for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the shot works as well as the IV and may be more convenient.
Los Alamitos, CaliforniaAges 18 years+ - NCT07287150RecruitingPhase 2
Inavolisib for metastatic castration-resistant prostate cancer
This trial tests a new drug called Inavolisib for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the drug can help slow the cancer's growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06533644RecruitingPhase 2
SYNC-T therapy study for advanced prostate cancer
This trial tests a new treatment called SYNC-T Therapy (SV-102) for men with metastatic castration-resistant prostate cancer that has progressed after other treatments. The therapy is given directly into a tumor to help your immune system fight the cancer.
Sacramento, CaliforniaAges 18 years+ - NCT06380751RecruitingPhase 3
New targeted therapy for BRCA/PALB2-mutated HR+ breast cancer
This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.
Fountain Valley, CaliforniaAges 18 years+ - NCT05673148RecruitingPhase 3
Ablation treatment plus usual therapy for limited metastatic bowel cancer
This study tests whether adding “total ablation” (carefully destroying all visible small tumors using surgery, heat/cold treatment, and/or targeted radiation) to standard chemotherapy improves outcomes for people with limited spread of colorectal cancer. It may help by aiming to eliminate all known metastatic spots while you continue usual cancer treatment.
Beverly Hills, CaliforniaAges 18 years+ - NCT07226544RecruitingPhase 2
Ivonescimab before surgery for high-risk kidney cancer
This trial tests giving the drug ivonescimab before surgery for patients with high-risk clear cell kidney cancer. The goal is to see if it can help shrink the tumor and improve outcomes.
Duarte, CaliforniaAges 18 years+ - NCT06931340RecruitingPhase 3
Adding chemo to hormone therapy for advanced prostate cancer
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
Dublin, CaliforniaAges 18 years+ - NCT07594106RecruitingPhase 1/Phase 2
New immunotherapy for advanced prostate or kidney cancer
This trial tests new experimental drugs (REGN15505 and REGN4336) designed to target and attack cancer cells in advanced prostate cancer or kidney cancer. These drugs work by boosting your immune system to recognize and destroy cancer, and may be combined with other approved immunotherapy drugs.
Duarte, CaliforniaAges 18 years+ - NCT07293351RecruitingPhase 1/Phase 2
Testing pumitamig with other drugs for advanced kidney cancer
This study tests a new drug (pumitamig) alone or with ipilimumab or cabozantinib for advanced kidney cancer that cannot be removed by surgery. It aims to find effective treatment options for people whose cancer has spread or is locally advanced.
Palo Alto, CaliforniaAges 18 years+ - NCT03606967RecruitingPhase 2
Individualized vaccine added to standard treatment for metastatic triple-negative breast cancer
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
Orange, CaliforniaAges 18 years+ - NCT04752826RecruitingPhase 1/Phase 2
Testing BI-1808 plus Keytruda for advanced cancers
This trial tests a new cancer medicine (BI-1808) either alone or together with Keytruda (pembrolizumab) in people with advanced cancers. It may help by strengthening the immune system’s attack on cancer, especially if standard treatments are no longer working or aren’t suitable.
Duarte, CaliforniaAges 18 years+ - NCT04929223RecruitingPhase 1
Targeted drug study for metastatic colon or rectal cancer
This Phase 1 study tests targeted cancer treatments in people with metastatic colorectal cancer, using genetic “biomarker” results to match you to the right treatment group. It focuses first on safety, and also looks for early signs the treatment may work in specific tumor subgroups.
Duarte, CaliforniaAges 18 years+
Locally Advanced or Metastatic Solid Tumors trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting locally advanced or metastatic solid tumors studies listed above.
- City of Hope Comprehensive Cancer Center · 8 studies
- University of California, Irvine Medical Center / UC Irvine Health · 6 studies
- University of California, Los Angeles (UCLA) · 3 studies
- USC / Norris Comprehensive Cancer Center · 3 studies
- Cedars-Sinai Medical Center · 2 studies
- Local Institution · 2 studies
- Sutter Medical Center Sacramento · 2 studies
- UC Irvine Health · 2 studies
What taking part in a locally advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Locally Advanced or Metastatic Solid Tumors trials in other states
Common questions
- Are there locally advanced or metastatic solid tumors clinical trials in California?
- Yes. We're currently tracking 566 recruiting locally advanced or metastatic solid tumors studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a locally advanced or metastatic solid tumors study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New locally advanced or metastatic solid tumors studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.